Peter Brauchli
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Gargiulo P, Pignata S, Berardi S, Glimelius B, Scheithauer W, Ruhstaller T, Bodoky G, Herrmann R, Dietrich D, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Ther Adv Med Oncol 2019; 11:1758835918818351.
Jan 2, 2019Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Jan 2, 2019Ther Adv Med Oncol 2019; 11:1758835918818351
Gargiulo Piera, Pignata Sandro, Berardi Simona, Glimelius Bengt, Scheithauer Werner, Ruhstaller Thomas, Bodoky György, Herrmann Richard, Dietrich Daniel, Brauchli Peter
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.
Aug 16, 2017Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Aug 16, 2017Endocr Connect 2017; 6:549-556
Zweifel Martin, Sessa Cristiana, Schoenfeld Wolfgang, Tapia Coya, Brauchli Peter, Hawle Hanne, Pilop Christiane, Rothgiesser Karin M, Bigler Martin, Pagani Olivia, von Moos Roger, Weder Patrik, Riniker Salome, Thürlimann Beat
Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
Steffen T, Ruhstaller T, Brauchli P, Thierstein S, Schiesser M, Gloor B, Furrer M, Marti W, Huber O, Kettelhack C, Schnider A, Dietrich D, Swiss Group for Clinical Cancer Research (SAKK). Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer. Ann Surg 2017; 269:83-87.
Jul 24, 2017Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
Jul 24, 2017Ann Surg 2017; 269:83-87
Steffen Thomas, Ruhstaller Thomas, Brauchli Peter, Thierstein Sandra, Schiesser Marc, Gloor Beat, Furrer Markus, Marti Walter R, Huber Olivier, Kettelhack Christoph, Schnider Annelies, Dietrich Daniel, Swiss Group for Clinical Cancer Research (SAKK)
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
Clough-Gorr K, Noti L, Brauchli P, Cathomas R, Fried M, Roberts G, Stuck A, Hitz F, Mey U. The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients. BMC Med Inform Decis Mak 2013; 13:93.
Aug 23, 2013The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
Aug 23, 2013BMC Med Inform Decis Mak 2013; 13:93
Clough-Gorr Kerri M, Noti Lea, Brauchli Peter, Cathomas Richard, Fried Marius R, Roberts Gillian, Stuck Andreas E, Hitz Felicitas, Mey Ulrich
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
Sep 12, 2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Sep 12, 2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97:1085-91.
Feb 7, 2012A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Feb 7, 2012Haematologica 2012; 97:1085-91
Renner Christoph, Lohri Andreas, Gyan Emmanuel, Biaggi Christine, Cogliatti Sergio B., Bertoni Francesco, Ghielmini Michele, Brauchli Peter, Ketterer Nicolas, Bouabdallah Krimo, Trojan Andreas, Zinzani Pier Luigi, Gressin Rémy, Klingbiel Dirk, Dietrich Pierre-Yves, Hitz Felicitas, Bargetzi Mario, Mingrone Walter, Martinelli Giovanni, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
Jan 4, 2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Jan 4, 2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane
What is the value of the 21-gene recurrence score?
Brauchli P, Thürlimann B, Crowe S, Herrmann R. What is the value of the 21-gene recurrence score?. J Clin Oncol 2010; 28:e671-2.
Aug 30, 2010What is the value of the 21-gene recurrence score?
Aug 30, 2010J Clin Oncol 2010; 28:e671-2
Brauchli Peter, Thürlimann Beat, Crowe Susanne N, Herrmann Richard
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)
Jost C, Meyenberger C, Brauchli P, Bertschinger P, Frossard J, Knuchel J, Werth B, Metzger U, Bauerfeind P, Schuller J, Binek J, Ruhstaller T. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointest Endosc 2010; 71:1114-21.
Mar 20, 2010Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)
Mar 20, 2010Gastrointest Endosc 2010; 71:1114-21
Jost Christian, Meyenberger Christa, Brauchli Peter, Bertschinger Philipp, Frossard Jean-Louis, Knuchel Juerg, Werth Baseli, Metzger Urs, Bauerfeind Peter, Schuller Jan C, Binek Janek, Ruhstaller Thomas
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32:724-30.
Dec 1, 2009Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Dec 1, 2009Onkologie 2009; 32:724-30
Klaeser Bernd, Ruhstaller Thomas, von Moos Roger, Albrecht Susanne, Caspar Clemens, Pestalozzi Bernhard C, Zünd Michael, Brauchli Peter, Cescato-Wenger Corinne, Hany Thomas, Balmer-Majno Sabine, Widmer Lucas, Köberle Dieter, Schuller Jan C, Nitzsche Egbert, Lange Jochen